logo
  Join        Login             Stock Quote

Synta Pharmaceuticals (SNTA) Initiated As 'Buy' By Brean Capital; PT $12

 December 13, 2012 02:26 PM
 


(By Balachander) Synta Pharmaceuticals Corp. (NASDAQ: SNTA) shares were initiated with a "Buy" rating and price target of $12 by Brean Capital.

The brokerage wrote it expects several important catalysts for SNTA's lead drug candidate, Ganetespib, during 2013 with important Phase 2 data readouts in lung and breast cancer.

Brean Capital forecasts commercial launch of Ganetespib in 2015, with global sales in 2nd-line NSCLC alone reaching $1B by 2020.

The brokerage said its current sales forecasts for NSCLC do not yet contemplate any contribution from Japan or from expansion into earlier stage or maintenance lung cancer, as monotherapy, or in other indications such as metastic breast cancer.

[Related -Top Insider Purchases: AINV, BGCP, EPZM, OPK, PKY, SNTA]

SNTA has initiated the pivotal Phase 3 portion of the GALAXY program for 2nd-line NSCLC, and the brokerage expects the trial to fully enroll by YE13, with an interim analysis during 1H14 and final results by 2H14.

Meanwhile, Brean Capital expects the company to announce final PFS data for Ganetespib from the ongoing Phase 2b portion of the GALAXY program during 1H13, with overall survival from the trial maturing in 2H13.

The stock, which has been trading in the 52-week range of $3.57 to $9.85, traded 0.35 percent higher at $8.64 on Thursday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageXerox Corp. (XRX): An Insider’s $500,000 Insider Buy

Last week was a healthy week of insider buying as 194 companies reported purchase records. The number read on...

article imageQihoo 360 Technology Co Ltd. (QIHU) Q2 Earnings Preview: A Green Monday

Qihoo 360 Technology Co Ltd. (NYSE:QIHU) will report its second quarter 2014 financial results on Monday, read on...

article imageSix Stocks that Could Outperform in the next 90 days

Earlier today, Goldman Sachs put out its list of the 50 stocks that Matter Most. It’s a list of the 50 read on...

article imageFoot Locker, Inc. (FL) Q2 Earnings Preview: Running Past the Street View

Foot Locker, Inc. (NYSE:FL) plans to report financial results for its second quarter ended August 2, 2014 read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

QE3, ECB Or Bust
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.